Genomcore leads the debate on precision medicine and agentic AI at Inforsalud 2026
As a main sponsor of the event organized by SEIS, the company highlighted the importance of data sovereignty and clinical decision-oriented interoperability.
The true revolution is not just about improving diagnosis, but about using technology to automate processes and free up valuable time for healthcare professionals.
The Inforsalud 2026 congress, organized by the Spanish Society of Health Informatics (SEIS), has once again established itself as the leading forum for the digital transformation of the National Health System. In this edition, Genomcore played a prominent role, not only as a main sponsor but also as a driver of strategic debate regarding the future of personalized medicine and the large-scale integration of biomedical data.
Agentic AI: Beyond Diagnosis
During the technical session titled "Precision medicine, agentic AI, and sovereignty", Dr. Oscar Flores, CEO of Genomcore, analyzed the evolution of artificial intelligence toward agentic models. Unlike traditional algorithms, these agents are capable of executing complex tasks by unifying clinical, genomic, and administrative data.
To make this vision a reality at a population level, Genomcore showcased its BIMS platform, designed to manage massive volumes of biomedical data scalably while ensuring data sovereignty within a European framework of open and interoperable infrastructures.
Interoperability for Clinical Decision-Making
David G. Pisano, Clinical Bioinformatics Director at Genomcore, provided a pragmatic perspective during the panel discussion on "Interoperability and networked data." Pisano emphasized that interoperability should not be viewed merely as a technical challenge of file exchange, but as a vehicle for generating actionable clinical decisions.
The key points of his intervention focused on:
- Quality at the source: The sustainability of a connected healthcare system depends on data integrity from the moment of capture.
- Knowledge management: Moving toward the exchange of derived knowledge, allowing professionals to focus on patient treatment.
- Ecosystem incentives: The need to align all stakeholders so that technical collaboration translates into real value for the patient.
Conclusions
Genomcore's participation in Inforsalud 2026 reaffirms the company's commitment to overcoming current barriers in omic data management. The real transformation of the sector requires integrating heterogeneous data sources to achieve truly personalized medicine, where technology acts as an invisible ally that enhances human capacity within the healthcare environment.
